The European Drug Report 2026 provides a snapshot of Europe’s drug situation based on the latest data available. Europe’s overlapping markets for established and new drugs continue to evolve and are further complicated by the integration of diverted and fake pharmaceutical products, resulting in a wider range of risks, and challenging existing response models as never before. Here we provide a brief analytical commentary on key drug policy and practice issues emerging from this year’s report.

This page is part of the European Drug Report 2026, the EUDA’s annual overview of the drug situation in Europe.

• The drug situation in Europe in 2026 – an overview
• Cannabis and cannabinoid products are changing, as are the problems
• Cocaine’s accessibility fuels health concerns
• Synthetic drugs pose diverse health concerns
• Opioid harms continue to challenge responses
• At a glance
• Source data